Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

Ipilimumab 17Nivolumab 15incomplete Freund's adjuvant 8Cyclophosphamide 7CTLA-4 Antigen 7pembrolizumab 6Ranibizumab 6sargramostim 5Radiosurgery 5Blood Specimen Collection 5tebentafusp 4Temozolomide 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4MART-1 Antigen 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4Bevacizumab 4fludarabine phosphate 3fludarabine 3aflibercept 3Thalidomide 3Sunitinib 3Specimen Handling 3MAGEA3 protein, human 3Interleukin-2 3130-nm albumin-bound paclitaxel 3relatlimab 2olaparib 2montanide ISA 51 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Uveal Melanoma × Thalidomide × Clear all
NCT00005815 2013-06-19

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
Dermatologic

Uveal Melanoma, Melanoma

NCT00238329 2013-04-08

PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
32 enrolled
Dermatologic

Uveal Melanoma, Melanoma

NCT00072345 2013-01-18

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡